8B4R | pdb_00008b4r

Antimicrobial peptide capitellacin from polychaeta Capitella teleta in DPC (dodecylphosphocholine) micelles, monomeric form

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D NOESY	0.84 mM capitellacin, 10 % [U-99% 2H] D2O, 100 % water, 168 mM DPC	95% H2O/5% D2O	0.001 M	5.4	AMBIENT Pa	318	Bruker AVANCE III 600
2	2D TOCSY	0.84 mM capitellacin, 10 % [U-99% 2H] D2O, 100 % water, 168 mM DPC	95% H2O/5% D2O	0.001 M	5.4	AMBIENT Pa	318	Bruker AVANCE III 600
3	2D 1H-13C HSQC aliphatic	0.84 mM capitellacin, 10 % [U-99% 2H] D2O, 100 % water, 168 mM DPC	95% H2O/5% D2O	0.001 M	5.4	AMBIENT Pa	318	Bruker AVANCE III 600
4	2D 1H-13C HSQC aromatic	0.84 mM capitellacin, 10 % [U-99% 2H] D2O, 100 % water, 168 mM DPC	95% H2O/5% D2O	0.001 M	5.4	AMBIENT Pa	318	Bruker AVANCE III 600
5	3D 1H-15N NOESY	0.07 mM [U-15N] capitellacin, 5 % [U-99% 2H] D2O, 14 mM DPC	95% H2O/5% D2O	0.001 M	5.4	AMBIENT Pa	318	Bruker AVANCE III 800
6	3D HCCH-TOCSY	0.07 mM [U-15N] capitellacin, 5 % [U-99% 2H] D2O, 14 mM DPC	95% H2O/5% D2O	0.001 M	5.4	AMBIENT Pa	318	Bruker AVANCE III 800
7	3D 1H-13C NOESY	0.07 mM [U-15N] capitellacin, 5 % [U-99% 2H] D2O, 14 mM DPC	95% H2O/5% D2O	0.001 M	5.4	AMBIENT Pa	318	Bruker AVANCE III 800

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	800
2	Bruker	AVANCE III	600

NMR Refinement
Method	Details	Software
simulated annealing		CYANA

NMR Ensemble Information
Conformer Selection Criteria	structures with the least restraint violations
Conformers Calculated Total Number	200
Conformers Submitted Total Number	20
Representative Model	1 (target function)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	CYANA	3.98.13	Guntert, Mumenthaler and Wuthrich
2	structure calculation	CYANA	3.98.13	Guntert, Mumenthaler and Wuthrich
3	chemical shift assignment	CARA		Keller and Wuthrich
4	peak picking	CARA		Keller and Wuthrich
5	collection	TopSpin		Bruker Biospin

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.